Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ACTRN12626000078358) titled 'A first study in humans to test the safety, tolerability, and how the body processes different single doses of a new imaging agent, KUVA-01, given by intravenous infusion in healthy adult volunteers' on Jan. 21.
Study Type: Interventional
Study Design:
Purpose: Diagnosis
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Assignment: Parallel
Type of endpoint: Safety
Primary Sponsor: Kuva Labs Pty Ltd.
Condition:
Metabolic and endocrine cancers
Metabolic and endocrine cancers
Metabolic and Endocrine - Normal metabolism and endocrine development and function
Cancer - Any cancer
Interven...